Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

Scott A. Waldman, Michael Camilleri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Functional gastrointestinal disorders (FGIDs) and IBDs are two of the most prevalent disorders of the GI tract and consume a significant proportion of healthcare resources. Recent studies have shown that membrane-bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic targets in the treatment of FGIDs and IBDs. GC-C receptor activation by its endogenous paracrine hormones uroguanylin and guanylin, and the resulting intracellular production of its downstream effector cyclic GMP, occurs in a pH-dependent manner and modulates key physiological functions. These include fluid and electrolyte homeostasis, maintenance of the intestinal barrier, anti-inflammatory activity and regulation of epithelial regeneration. Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of these receptors in treating GI disorders, including chronic idiopathic constipation and irritable bowel syndrome-constipation. This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.

Original languageEnglish (US)
Pages (from-to)1543-1552
Number of pages10
JournalGut
Volume67
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Guanylate Cyclase
Gastrointestinal Diseases
Constipation
Gastrointestinal Tract
Paracrine Communication
Irritable Bowel Syndrome
Cyclic GMP
Therapeutics
Electrolytes
Regeneration
Homeostasis
Anti-Inflammatory Agents
Maintenance
Hormones
Delivery of Health Care
Membranes
Health

Keywords

  • chronic idiopathic constipation
  • guanylate cyclase C
  • irritable bowel syndrome-constipation
  • linaclotide
  • plecanatide
  • uroguanylin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. / Waldman, Scott A.; Camilleri, Michael.

In: Gut, Vol. 67, No. 8, 01.08.2018, p. 1543-1552.

Research output: Contribution to journalArticle

Waldman, Scott A. ; Camilleri, Michael. / Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. In: Gut. 2018 ; Vol. 67, No. 8. pp. 1543-1552.
@article{21d759e9fbb744cf9150f7c0bbf621d2,
title = "Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders",
abstract = "Functional gastrointestinal disorders (FGIDs) and IBDs are two of the most prevalent disorders of the GI tract and consume a significant proportion of healthcare resources. Recent studies have shown that membrane-bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic targets in the treatment of FGIDs and IBDs. GC-C receptor activation by its endogenous paracrine hormones uroguanylin and guanylin, and the resulting intracellular production of its downstream effector cyclic GMP, occurs in a pH-dependent manner and modulates key physiological functions. These include fluid and electrolyte homeostasis, maintenance of the intestinal barrier, anti-inflammatory activity and regulation of epithelial regeneration. Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of these receptors in treating GI disorders, including chronic idiopathic constipation and irritable bowel syndrome-constipation. This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.",
keywords = "chronic idiopathic constipation, guanylate cyclase C, irritable bowel syndrome-constipation, linaclotide, plecanatide, uroguanylin",
author = "Waldman, {Scott A.} and Michael Camilleri",
year = "2018",
month = "8",
day = "1",
doi = "10.1136/gutjnl-2018-316029",
language = "English (US)",
volume = "67",
pages = "1543--1552",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

AU - Waldman, Scott A.

AU - Camilleri, Michael

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Functional gastrointestinal disorders (FGIDs) and IBDs are two of the most prevalent disorders of the GI tract and consume a significant proportion of healthcare resources. Recent studies have shown that membrane-bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic targets in the treatment of FGIDs and IBDs. GC-C receptor activation by its endogenous paracrine hormones uroguanylin and guanylin, and the resulting intracellular production of its downstream effector cyclic GMP, occurs in a pH-dependent manner and modulates key physiological functions. These include fluid and electrolyte homeostasis, maintenance of the intestinal barrier, anti-inflammatory activity and regulation of epithelial regeneration. Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of these receptors in treating GI disorders, including chronic idiopathic constipation and irritable bowel syndrome-constipation. This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.

AB - Functional gastrointestinal disorders (FGIDs) and IBDs are two of the most prevalent disorders of the GI tract and consume a significant proportion of healthcare resources. Recent studies have shown that membrane-bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic targets in the treatment of FGIDs and IBDs. GC-C receptor activation by its endogenous paracrine hormones uroguanylin and guanylin, and the resulting intracellular production of its downstream effector cyclic GMP, occurs in a pH-dependent manner and modulates key physiological functions. These include fluid and electrolyte homeostasis, maintenance of the intestinal barrier, anti-inflammatory activity and regulation of epithelial regeneration. Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of these receptors in treating GI disorders, including chronic idiopathic constipation and irritable bowel syndrome-constipation. This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.

KW - chronic idiopathic constipation

KW - guanylate cyclase C

KW - irritable bowel syndrome-constipation

KW - linaclotide

KW - plecanatide

KW - uroguanylin

UR - http://www.scopus.com/inward/record.url?scp=85049127200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049127200&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2018-316029

DO - 10.1136/gutjnl-2018-316029

M3 - Article

C2 - 29563144

AN - SCOPUS:85049127200

VL - 67

SP - 1543

EP - 1552

JO - Gut

JF - Gut

SN - 0017-5749

IS - 8

ER -